louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04411017: Protocol for Optimizing Colonoscopy Preparation in Patients With Inflammatory Bowel Disease
Official title: Protocol for Optimizing Colonoscopy Preparation in Patients With Inflammatory Bowel Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inflammatory Bowel Diseases
Keywords: Colonoscopy
Inflammatory Bowel Diseases
Lead sponsor: Hospital Universitario La Paz
Sponsor class: OTHER
First posted: 2020-06-01
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Clinical trial evaluating efficacy of bowel cleansing solutions in patients with Inflammatory Bowel Disease.

Detailed description: Simple blind, randomized study evaluating efficacy of 1LPEG vs 2L PEG vs 2L sodium picosulfate in bowel cleansing of patients diagnosed of Inflammatory Bowel Disease undergoing diagnostic or follow-up routine colonoscopy.

Eligibility criteria: Inclusion Criteria:

* Patients between 18y and 90y
* Patients with a diagnosis of IBD undergoing follow-up or screening colonoscopy

Exclusion Criteria:

* Patients \<18y or \>90y
* Pregnant Women
* Patients with a past history of inadequate bowel cleansing in a colonoscopy performed in the previous 12 months prior to initiation of study
* Patients with a history of bowel resection
* Patients undergoing therapeutic colonoscopy
* Patients unable to understand study protocol

Primary outcomes:
measure: Bowel cleansing
timeFrame: 1 year
Secondary outcomes:
measure: Treatment related adverse events
timeFrame: 1 year
measure: Preparation Tolerability: total volume of solution finally taken by the patient
timeFrame: 1 year
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
state: Madrd
Study officials:
affiliation: Hospital Universitario La Paz. IdiPaz. Universidad Autónoma de Madrid.
name: Maria Dolores Martin Arranz, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00550017: A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)
Official title: A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects With Advanced Cancer (Schedule 2)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Tumors
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2007-10-26
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493) in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate (BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian, renal or breast cancer (in Phase 2 portion)


Eligibility criteria: Inclusion Criteria:

* Advanced cancer, excluding cancer in the blood
* Availability of 10 tumor tissue slides

Exclusion Criteria:

* Known brain metastases
* Severe nerve damage
* Significant cardiovascular disease
* Inadequate blood counts
* Inadequate liver or kidney function
* Inadequate thyroid function or uncontrolled thyroid disease

Primary outcomes:
measure: To determine the Maximum Tolerated Dose, the Dose Limiting Toxicity and the recommended dose of Epofolate (BMS-753493)
timeFrame: at the end of the study
Secondary outcomes:
measure: To evaluate the safety and exposure levels of Epofolate (BMS-753493) in the body and the anticancer activity of Epofolate (BMS-753493)
timeFrame: every 21 days
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Ottawa
country: Canada
facility: Local Institution
state: Ontario
city: Toronto
country: Canada
facility: Local Institution
state: Ontario
city: Newcastle Upon Tyne
country: United Kingdom
facility: Local Institution
state: Tyne And Wear
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT04117217: Risk Factors for Thrombosis in Children With Central Venous Lines
Official title: Analysis of Laboratory Markers to Predict Risk of Catheter Related Thrombosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pediatric Venous Thromboembolism
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2019-10-07
Enrollment: 200
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric patients having central venous line placement

Brief summary: This project addresses the role of lab markers around the time of central line placement in predicting risk of thrombosis in pediatric patients with central venous lines being placed. The project proposes an innovative way to predict higher risk of thrombosis in the pediatric population to give clinicians a valid tool to guide clinical practice for these patients.


Eligibility criteria: Inclusion Criteria:

* Patients over 5 kg and less than 18 years of age.
* Patients having a central venous catheter or cardiac catheterization performed

Exclusion Criteria:

* prior history of thrombosis
* patients with hemophilia A or B

Primary outcomes:
measure: Thrombosis
timeFrame: within one year of enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Tucson
country: United States
facility: University of Arizona
state: Arizona
Study officials:
References:
Clinical trial NCT05581017: Association of Cephalosporin Resistance and Surgical Site Infections in Patients Undergoing Pancreaticoduodenectomy
Official title: Association of Cephalosporin Resistance in Intraoperative Biliary Cultures with Surgical Site Infections in Patients Undergoing Pancreaticoduodenectomy - a Retrospective Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgical Site Infection
Pancreaticoduodenectomy
Biliary Tract Infection Bacterial
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2022-10-14
Enrollment: 376
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients undergoing pancreaticoduodenectomy in a single high volume center between May 23rd 2016 to October 29th 2020.

Brief summary: Preoperative biliary drainage predisposes the bile to be contaminated with bacteria of the duodenum. These bacteria colonizing the bile are a potential source for surgical site infections after pancreaticoduodenectomy and many international guidelines recommend the use of cephalosporines as microbial prophylaxis before surgery. The aim of this study was to assess the incidence of bacteria in bile, their resistance profiles and association to surgical site infections in relation to timing of surgery after preoperative biliary drainage in order to better guide antibiotic use.


Eligibility criteria: Inclusion Criteria:

* All patients undergoing pancreaticoduodenectomy between May 23rd 2016 to October 29th 2020

Exclusion Criteria:

* Patients without intraoperative biliary culture
* Patients with unknown date of preoperative biliary culture

Primary outcomes:
measure: Rate of surgical site infections
timeFrame: 30 days post operatively
measure: Prevalence of cephalosporin resistance in intraoperative biliary cultures
timeFrame: At the time of operation
Secondary outcomes:
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki Central Hospital
Study officials:
affiliation: Gastroenterological Surgery, Helsinki University Hospital
name: Timo O Tarvainen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00924417: A Distraction Protocol for Peripheral Intravenous (IV) Placement in the Pediatric Emergency Department
Official title: A Distraction Protocol for Peripheral IV Placement in the Pediatric Emergency Department
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Pain
Keywords: Pain associated with peripheral intravenous line placement
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Sponsor class: OTHER
First posted: 2009-06-19
Enrollment: 55
Sex: ALL
Minimum age (years): 4
Maximum age (years): 9
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a randomized, controlled trial of a distraction protocol for peripheral intravenous line placement in the pediatric emergency department. Patients and parents will be randomized to one of two interventions: routine care or a teaching session about the cognitive technique known as distraction. The study seeks to enroll children ages 4-9, who are cognitively normal, who are without significant chronic medical illness, who are receiving intravenous line placement as part of routine care in the pediatric emergency department. Study investigators hypothesize that patients in the intervention group will report less pain than patients in the control group.

Detailed description: Routine care patients will have intravenous lines placed in the usual manner.

Intervention patient families will have a teaching session about distraction techniques, and distraction will be used during the intravenous line placement.

Eligibility criteria: Inclusion Criteria:

* Ages 4 - 9
* Requiring IV placement for medical care in emergency department
* Child cognitively normal

Exclusion Criteria:

* No significant chronic medical conditions
* No IV in past 3 years

Primary outcomes:
measure: Faces Pain Scale Revised as reported by child
timeFrame: To be completed 5 minutes after IV placement
Secondary outcomes:
measure: Visual Analog Scales to be completed by parent in order to measure: parent distress, patient/child pain, patient/child distress
timeFrame: 5 minutes after IV completion
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Ann & Robert H. Lurie Children's Hospital of Chicago
state: Illinois
Study officials:
affiliation: Ann & Robert H Lurie Children's Hospital of Chicago
name: Elizabeth Powell, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03313817: Pre and Post-arterial Recanalization Imaging of Central Retinal Artery Occlusions (CRAO)
Official title: Pre and Post-arterial Recanalization Imaging of Central Retinal Artery Occlusions (CRAO)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Retinal Artery Occlusion
Magnetic Resonance Imaging
Diagnosis
Etiology
Prognosis
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2017-10-18
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients hospitalized for CRAO ≤ 48 hours.

Brief summary: Central retinal artery occlusions (CRAO) are the equivalent of an ischemic stroke at the retinal level. They share the same risk factors and common pathology. The diagnosis of a CRAO is clinically based on the sudden occurrence of a decrease in deep visual acuity with fundamentally signs of reactive ischemia.

Small studies have highlighted the value of cerebral MRI (Magnetic Resonance Imaging) in CRAO with almost 25% of ischemic strokes found on diffusion sequences and the demonstration of a correlation between anomalies in diffusion sequence and the probability of a pathology with a high risk of recurrence (carotid stenosis or emboligenic cardiopathy). But there are usually few radiological signs that allow a direct positive diagnosis of CRAO, an etiologic diagnosis or a prognosis. This descriptive study will focus on CRAO at the diagnostic and post-treatment phases in the short and medium term, in order to (i) identify imaging etiologic signs of CRAO with specific sequences from a 3 Tesla MRI, (ii) identify positive diagnostic signs of CRAO with the same specific sequences, (iii) correlate these signs with the visual prognosis one month after the CRAO.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* CRAO (onset of symptoms ≤ 48 hours)
* Consent to participate in the study

Exclusion Criteria:

- Contraindications to 3 Tesla MRI

Primary outcomes:
measure: Contrast enhancement of the ophthalmic artery
timeFrame: Baseline
measure: Presence of a thrombus
timeFrame: Baseline
measure: Presence of an arterial stenosis of the supra aortic trunks
timeFrame: Baseline
measure: Hypersignal of the ophthalmic artery in diffusion
timeFrame: Baseline
measure: Restriction of the apparent diffusion coefficient (ADC) at the optic nerve level and at the papilla level
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Ophtalmologique A. de Rothschild
Study officials:
References:
Clinical trial NCT01275417: Using Different Kinds of B-cun Scales to Mark Some Acupoints at Governor Vessel on the Head
Official title: Using Different Kinds of B-cun Scales to Mark Some Acupoints at Governor Vessel on the Head
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: to Research the Feasibility of the Proportional Bone(Skeletal) Measurement Method on the Head Region.
Keywords: Acupuncture
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
Collaborators: name: Graduate Institute of Acupuncture Science, China Medical University
First posted: 2011-01-12
Enrollment: 160
Sex: FEMALE
Minimum age (years): 6
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Sampling method: PROBABILITY_SAMPLE
Study population: community sample: This experiment will recruit 100 volunteers age ranged 18-80 years old and 60 children under 10 years old.

Brief summary: We are expecting that there are remarkable differences location at BaiHui(GV20) or Houding(GV19)showing from same person in our study.


Eligibility criteria: Inclusion Criteria:

healthy volunteers

Exclusion Criteria:

1. craniectomy
2. Psychotic symptoms

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01050517: Safety and Efficacy of Drug Combinations Against Triple Infections
Official title: Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parasitic Diseases
Lead sponsor: DBL -Institute for Health Research and Development
Sponsor class: OTHER
First posted: 2010-01-15
Enrollment: 250
Sex: ALL
Minimum age (years): 5
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomised, controlled, double blinded clinical study investigates the safety and efficacy of the combination of albendazole, ivermectin and praziquantel in the treatment of children aged 5-18 years co-infected with lymphatic filariasis, schistosomiasis and soil-transmitted helminthiasis.


Eligibility criteria: Inclusion Criteria:

* Those who will be in class one to six by the time of study
* Aged 5-18 years and found infected with either SCH, any STH or LF for treatment groups 1,2 or 3 or infected with both SCH and LF for treatment group 4 and infected with all the three for treatment group 5
* Who are willing and consent and whose parents will consent, will be included in the study.

Exclusion Criteria:

* Those with acute and chronic diseases other than the targeted infections and those with a history of any serious adverse drug reactions will not be included in the study.
* Children with total bilirubin \> 50µmol/L and ALAT (Alanine transferase) \> 70IU/L will not qualify for recruitment.

Primary outcomes:
measure: adverse reactions
timeFrame: 6 weeks
Secondary outcomes:
measure: Efficacy of treatment
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Kampala
country: Uganda
facility: Vector Control Division
Study officials:
References:
citation: Namwanje H, Kabatereine N, Olsen A. A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda. Trans R Soc Trop Med Hyg. 2011 Apr;105(4):181-8. doi: 10.1016/j.trstmh.2010.11.012. Epub 2011 Feb 25.
Clinical trial NCT03420417: Respiratory Mechanics in Intensive Care Patients
Official title: Study of the Respiratory Mechanics Characteristics With Esophageal PREssure Measurements in Mechanically Ventilated Patients in IntensivE caRe Unit
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Intensive Care
Ventilator Lung
Keywords: Mechanical ventilation
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2018-02-05
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study aims at assessing the respiratory mechanics of intubated patients in intensive care unit.


Eligibility criteria: Inclusion Criteria:

* Age \> or = 18 years
* Invasive mechanical ventilation on tracheal tube
* Treatment with neuromuscular blocking agents
* Nasogastric tube needed for enteral nutrition

Exclusion Criteria:

* Lack of free and informed consent
* Pregnant or breastfeeding woman
* Contra-indication to esophageal pressure measurement catheter

Primary outcomes:
measure: Chest wall compliance measurement (mL/cmH2O)
timeFrame: 1 hour
Secondary outcomes:
measure: lung compliance measurement (mL/cmH2O)
timeFrame: 1 hour
measure: End expiratory lung volume (mL)
timeFrame: 1 hour
Other outcomes:
Locations:
city: Angers
country: France
facility: University hospital
Study officials:
affiliation: University Hospital, Angers
name: François Beloncle, MCU-PH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Beloncle FM, Merdji H, Lesimple A, Pavlovsky B, Yvin E, Savary D, Mercat A, Meziani F, Richard JC. Gas Exchange and Respiratory Mechanics after a Cardiac Arrest: A Clinical Description of Cardiopulmonary Resuscitation-associated Lung Edema. Am J Respir Crit Care Med. 2022 Sep 1;206(5):637-640. doi: 10.1164/rccm.202111-2644LE. No abstract available.
Clinical trial NCT02474017: An Open Study to Assess the Robustness of the CRC749 Inhaler
Official title: An Open Study to Assess the Robustness of the CRC749 Device by Pharmaceutical Performance Following Twice Daily Dosing of MGR001 Administered Via Oral Inhalation in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Asthma
COPD
Keywords: Inhaler
Adolescent
Lead sponsor: Viatris Inc.
Sponsor class: INDUSTRY
First posted: 2015-06-17
Enrollment: 111
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To confirm the robustness of the CRC749 inhaler.


Eligibility criteria: Inclusion Criteria:

1. Males and females at least 12 years of age.
2. A clinical diagnosis for at least 12 weeks prior to screening of asthma or COPD and stable treatment.
3. Spirometry following salbutamol showing FEV1 ≥40% of predicted normal and FEV1/FVC ratio \<0.7 for COPD subjects.
4. Spirometry without salbutamol showing FEV1 ≥50% of predicted normal for asthma subjects.
5. Ability to use the CRC749 inhaler.

Exclusion Criteria:

1. Other chronic or active respiratory disorder or symptoms of, or treatment for a COPD or asthma exacerbation during the 28 days preceding screening.
2. History of long QT syndrome or screening ECG with QTcF greater than 480 milliseconds.
3. Current evidence of, or history within the 6 months prior to screening of unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, or myocardial infarction.
4. Subjects in whom Advair(R) Diskus(R) / Seretide(R) Accuhaler(R) are contra-indicated.

Primary outcomes:
measure: In vitro Measurement of Emitted Dose
timeFrame: 3 Weeks
Secondary outcomes:
measure: Adverse Events
timeFrame: 3 Weeks
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Mylan Investigational Site
city: Manchester
country: United Kingdom
facility: Mylan Investigational Site
Study officials:
affiliation: Mylan Pharma UK Ltd.
name: Richard Allan
role: STUDY_DIRECTOR
References:
citation: Allan R, Canham K, Wallace R, Singh D, Ward J, Cooper A, Newcomb C. Usability and Robustness of the Wixela Inhub Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2021 Apr;34(2):134-145. doi: 10.1089/jamp.2020.1603. Epub 2020 Aug 31.
Clinical trial NCT02773017: The ED50 of DEX for Providing Sedation in Different Female Age Group
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Combined Spinal-epidural Anesthesia
Keywords: sedation
age
dexmedetomidine
Lead sponsor: Guangzhou General Hospital of Guangzhou Military Command
Sponsor class: OTHER
First posted: 2016-05-16
Enrollment: 90
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dexmedetomidine(DEX) could provide dose-dependent sedation , analgesia , anti-anxiety and inhibition of sympathetic nerves and other effects. Because of its minimal impact on the respiratory , currently it was more and more widely used to sedate patients undergoing regional anesthesia.Many anesthetic pharmacokinetics and pharmacodynamics are often affected by age, and current studies with regard to the effects of age on dexmedetomidine pharmacodynamic are rare. This study was designed to explore the right DEX dose of different female Age of patients to produce suitable sedation.Dexmedetomidine be used in patients with combined spinal and epidural anesthesia for sedation,which is monitored by the Narcotrend,during the operation.The relation between Narcotrend index (NTI) and the depth of sedation for patients is also investigated.

Detailed description: 90 patients scheduled for combined spinal epidural spinal anesthesia were included in one of three groups. In each group,determination of median effective (ED50) doses was performed by the Dixon up-and-down method, an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1 μg/kg in first three turning points and 0.05μg/kg in the last three turning points.Initial doses was 1.4μg/kg, .Sedative efficacy was defined as an OAA/S of ≤3,30 min after the beginning of drug administration.

Eligibility criteria: Inclusion Criteria:

1. ASA Ⅰ \~ Ⅱ patient undergoing lower extremity surgery
2. Written informed consent from the patient or the relatives of the participating patient.
3. BMI:18.0～25.0kg/m2

Exclusion Criteria:

1. Mental illness can not match
2. epidural anesthesia contraindicated
3. People who have Slow-type arrhythmias
4. People who were language or hearing impaired
5. Sensory block reached to T8 or higher.
6. People who had lung infection or sleep apnea syndrome.
7. Pregnancy
8. Chronic renal failure
9. Alcohol or drug abuse
10. Already taking gabapentin, pregabalin, benzodiazepin or antidepression drug

    -

    -

Primary outcomes:
measure: The ED50 of DEX for providing sedation
timeFrame: 30min after the start of the infusion
Secondary outcomes:
measure: The ED95 of DEX
timeFrame: 30min after the start of the infusion
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangzhou Military Region General Hospital, Department of Anesthesiology
state: Guangdong
Study officials:
References: